[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636937":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":35,"locations":43,"responsibleParty":58,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":92,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Icahn School of Medicine at Mount Sinai","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sotagliflozin","ACTIVE_COMPARATOR","Sotagliflozin 400mg per day orally",[13],"Drug: Sotagliflozin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching Placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sotagliflozin 400mg starting prior to the first scheduled anthracycline infusion",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo starting prior to the first scheduled anthracycline infusion",[15],[30,33],{"name":31,"affiliation":5,"role":32},"Carlos G Santos-Gallego, MD","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":5,"role":32},"Santos-Gallego, MD",[36,40],{"name":31,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","212-241-8484","carlos.santos-gallego@mssm.edu",{"name":41,"role":37,"phone":38,"phoneExt":25,"email":42},"Juan Antonio Requena-Ibanez","juanantonio.requenaibanez@mssm.edu",[44],{"facility":5,"status":25,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"New York","10029","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-74.00597,40.71427,{"lat":53,"lon":52},[56],{"name":57,"role":32,"phone":25,"phoneExt":25,"email":25},"Carlos G Santos-Gallego",{"type":32,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Carlos Santos-Gallego","Cardiologist, Assistant Professor of Cardiology",[62],{"name":63,"class":6},"American Heart Association","100636937","phase-2-sotagliflozin-as-prevention-of-anthracycline-related-cardiotoxicity-100636937",false,"NCT07572175","Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity","SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)","SPARTACUS","Inclusion Criteria\n\n* Patients ≥ 18 years\n* Newly diagnosed lymphoma\n* Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg\u002Fm2)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n\nExclusion Criteria\n\n* Prior anthracycline treatment\n* Previous malignancy requiring any chemotherapy or radiotherapy\n* Previous treatment with SGLT2i (eg due to T2DM) or SGLT1\u002F2i\n* Previous heart failure (HF patients should already be on SGLT2i as per guidelines)\n* LVEF\\\u003C40% (even in the absence of HF):\n* Pregnancy or breastfeeding\n* Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)","ALL","18 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This project aims to determine the benefits of the dual SGLT1\u002F2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.",[82,83,84,85],"Anthracycline-induced Cardiotoxicity","Lymphoma","Chemotherapy","Cardiotoxicity",[87,88,89,90,91],"anthracycline","left ventricular dysfunction","cardiotoxicity","SGLT inhibitors","prevention","NOT_YET_RECRUITING","2026-04-30",{"date":95,"type":96},"2026-05-07","ACTUAL",{"date":98,"type":76},"2026-07",{"date":100,"type":76},"2029-10",{"name":5,"class":6},1]